Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Cancer Screening Tie-up: Hong Kong's Cirina Merges With GRAIL, an Illumina Spin-Out

publication date: Jun 1, 2017
Cirina, a Hong Kong cancer diagnostics company, will merge with GRAIL, a Menlo Park startup, which is also developing non-invasive early-stage molecular cancer diagnostics. GRAIL is a spin-out from Illumina that has raised an impressive $1 billion in venture capital. The merger combines GRAIL's deep pockets, which will fund large-scale clinical trials, with one of the scientific leaders in the field, Dennis Lo, DM, DPhil, a co-founder of Cirina. He is joined by other co-founders of Cirina, Rossa Chiu and Allen Chan at the Chinese University of Hong Kong, and lead investor, Decheng Capital. More details....

Stock Symbol: (NSDQ: ILLM)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China